Table 3. Multivariate Cox regression analysis of clinicopathological factors and TOP2A overexpression, with respect to relapse-free survival among patients with luminal B breast cancer (n = 315).
| factors | n | hazard ratio (95% CI) | p value | |
|---|---|---|---|---|
| age | 50≥ | 69 | 1 | 0.30 |
| 50< | 246 | 0.68 (0.34–1.36) | ||
| T stage | 2 cm≥ | 177 | 1 | 0.036 |
| 2 cm< | 138 | 2.15 (1.05–4.39) | ||
| Nodal status | netative | 202 | 1 | 0.012 |
| positive | 113 | 2.37 (1.21–4.62) | ||
| PgR | positive | 249 | 1 | 0.57 |
| netative | 66 | 1.26 (0.57–2.78) | ||
| nuclear grade | 1, 2 | 236 | 1 | 0.85 |
| 3 | 79 | 1.1 (0.55–2.30) | ||
| Ki67 (continuous value) | 1.02 (1.00–1.04) | 0.11 | ||
| adjuvant chemotherapy | no | 183 | 1 | 0.76 |
| yes | 132 | 0.89 (0.42–1.88) | ||
| adjuvant radiation therapy | no | 105 | 1 | 0.29 |
| yes | 210 | 0.71 (0.31–1.35) | ||
| TOP2A overexpression | no | 136 | 1 | 0.002 |
| yes | 179 | 4.00 (1.65–9.54) |
Abbreviations: PgR; progesteron receptor.